INTRODUCTION
The role of prostacyclin (prostaglandin I # ), a naturally occurring vasodilator, administered intravenously in the form of epoprostenol for the treatment of pulmonary hypertension is well established [1] . There are increasing data supporting a role for nebulized prostacyclin therapy in pulmonary hypertension [2, 3] . Furthermore, continuous infusions of prostacyclin have been shown to produce clinical improvement and improved pulmonary haemodynamics in patients with primary pulmonary hypertension who do not have an acute vasodilator response [4] . It has been suggested that epoprostenol has antiKey words : nitric oxide, prostacyclin, pulmonary hypertension.
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Correspondence : Dr P. A. Corris. mitogenic, anti-thrombotic and vascular remodelling effects that would explain the benefits, but no definite mechanisms have been proposed.
We have observed that nebulized epoprostenol, given as a single daily dose, produced sustained symptomatic improvement in patients with pulmonary hypertension complicating left-to-right cardiac shunts. We hypothesized that nebulized epoprostenol may be acting to alter the vasoconstrictor\vasodilator balance, increasing vascular nitric oxide (NO) release, and that this could be assessed by measurement of exhaled NO (eNO). NO is an important vasodilator, and previous animal studies have demonstrated that eNO reflects NO production from the pulmonary circulation [5] . Levels of eNO are reduced in patients with pulmonary hypertension due to systemic sclerosis [6] . We therefore studied the effects of nebulized epoprostenol on eNO in patients with pulmonary hypertension complicating congenital heart disease and in normal healthy controls.
METHODS

Subjects
Nine patients with confirmed and symptom-limiting (NYHA Class III-IV) pulmonary hypertension complicating atrial\ventricular septal defects or patent ductus arteriosus were selected, and gave informed consent to participate in the study, the protocol of which was approved by the local ethics committee. Nine healthy volunteers also gave informed consent to participation. Subjects with a history of asthma or interstitial lung disease, or those reporting symptoms consistent with an intercurrent respiratory tract infection, were excluded. All patients and control volunteers were non-smokers. There were no major clinical differences between the patients apart from the underlying diagnosis. Volunteers did not undergo haemodynamic or echocardiographic assessment. Subject characteristics are listed in Table 1 .
Table 1 Subject characteristics
Diagnoses : PDA, patent ductus arteriosus ; ASD, atrial septal defect ; VSD, ventricular septal defect. Patient pulmonary haemodynamics are expressed in mmHg. Pulmonary artery systolic pressure (PASP) was obtained by Doppler echocardiographic assessment of tricuspid regurgitation. Mean pulmonary artery pressure (MPA) was measured directly at right heart catheterization. ∆eNO is the change in eNO levels between baseline and 18 h after nebulization. 
NO measurement eNO and nasal NO were measured using a standard validated chemiluminescence method [7] (LR2000, 2.2 ; Logan Research), and expressed as parts per billion (p.p.b.). Measurements were made before, immediately after and 18 h after nebulization. eNO was measured at the plateau of exhaled CO # against a fixed airway resistance and flow rate in order to represent NO production of the distal airspaces. In addition to measurement of eNO in control subjects, nasal NO was measured at an inspiratory breath hold in all subjects, in order to exclude possible irritant effects of the nebulized solution on the respiratory epithelium that may result in a nonspecific increase in NO production.
Delivery of nebulized prostacyclin
Prostacyclin was administered as the sodium salt of epoprostenol (Flolan ; Wellcome) dissolved in glycine buffer, pH 10.5. A dose of 100 µg in a volume of 10 ml was nebulized on air, using a high-flow compressor (Medicaid ; CR60) and mouthpiece system (Medicaid ; Ventstream), with nasal occlusion throughout.
Statistical analysis
Analysis of covariance (ANCOVA) was used to assess the differences in eNO between the patient and control groups. The relationship between pulmonary artery pressure and change in eNO in the patient group was assessed using linear regression analysis. A P value of 0.05 was regarded as significant. Statistical analysis was performed using MiniTab for Windows.
RESULTS
All subjects completed nebulization without adverse events ; in particular, no subjects reported irritation or developed cough. eNO levels at baseline, immediately after and 18 h after nebulization in patients and controls are displayed in Figures 1(a) and 1(b) respectively. There was no significant difference between the two groups at baseline (patients, 7.2p0.8 p.p.b. ; controls, 7.7p 1.8 p.p.b.). At 18 h after nebulization, eNO levels were significantly elevated in the patient group (11.6p 2.3 p.p.b.) compared with controls (6.6p1.2 p.p.b. ; P l 0.032). Nasal NO measurements in patients and controls did not show any significant change between baseline and 18 h levels (patients 152p66 and 158p69 p.p.b. respectively ; controls, 489p24 and 487p11 p.p.b. respectively). There was no relationship in patients between the Individual data are shown, and are also summarized as meanspS.E.M. There was no difference between the patients with pulmonary hypertension (a) and control subjects (b) at baseline or immediately after nebulization. However, there was a significant difference in eNO between the two groups 18 h after nebulization (P l 0.032). 
DISCUSSION
This study confirms a recent finding that there is a difference in the response of the pulmonary circulation to nebulized prostacyclin in pulmonary hypertensive patients compared with normal controls [8] . The authors of the previous study [8] described an acute increase in pulmonary blood flow in patients that was not seen in normal subjects, supporting the concept that there is no resting vasoconstrictor tone in the normal pulmonary circulation.
Our data show that, while there was no difference in levels of eNO between patients and controls at baseline, there was a very different response of eNO to inhaled prostacyclin. The data indicate a statistically significant difference between the two groups ; moreover, the individual increases in eNO seen in a number of the patients were well in excess of what we have observed to be the limits of normal day-to-day variability (2.0 p.p.b.) [9] , and imply a true biological difference.
The reason for this difference remains unclear. The lack of effect on eNO in the control group, along with the failure to increase nasal NO levels, suggests that an irritant effect on the airway epithelium due to the high pH of the solution is unlikely, and that the increased eNO reflects increased local production within the lung vasculature. It may be of relevance that patients with secondary pulmonary hypertension have been demonstrated to have an apparently reduced circulating level of prostacyclin [10] . It is possible that nebulized prostacyclin restores a vasoconstrictor\vasodilator balance, with the delayed nature of the increase in eNO suggesting a possible action through transcriptional effects on NO synthesis.
These data help to explain our observations on the benefits of nebulized prostacyclin beyond its direct and short-lived pharmacological actions, and support a rationale for long-term intermittent treatment. Studies are required to confirm these observations and to correlate increases in eNO with functional indices and objective physiological improvements.
